Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-14
DOI
10.1038/s41598-019-38585-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies
- (2017) Nisha Bansal et al. Cancer Control
- PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer
- (2015) Aki Miyasaka et al. GYNECOLOGIC ONCOLOGY
- Sequential Chemotherapy and Radiotherapy in the Sandwich Method for Advanced Endometrial Cancer
- (2015) Huiqiao Gao et al. MEDICINE
- Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
- (2014) Hui Jun Lim et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
- (2013) B. Weigelt et al. CLINICAL CANCER RESEARCH
- The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis
- (2013) Hyun Jong Park et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
- (2013) G. E. Konecny et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
- (2012) B. M. Slomovitz et al. CLINICAL CANCER RESEARCH
- Contemporary management of endometrial cancer
- (2012) Jason D Wright et al. LANCET
- Markers for individualised therapy in endometrial carcinoma
- (2012) Helga B Salvesen et al. LANCET ONCOLOGY
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy
- (2012) Meihua Sui et al. RADIOTHERAPY AND ONCOLOGY
- Emerging therapeutic targets in endometrial cancer
- (2011) Konstantin J. Dedes et al. Nature Reviews Clinical Oncology
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–Results from two randomised studies
- (2010) Thomas Hogberg et al. EUROPEAN JOURNAL OF CANCER
- A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the “sandwich” method for high risk endometrial carcinoma
- (2010) Melissa A. Geller et al. GYNECOLOGIC ONCOLOGY
- Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
- (2008) G E Konecny et al. BRITISH JOURNAL OF CANCER
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC)
- (2007) Abbie L. Fields et al. GYNECOLOGIC ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started